4363 studies found for:    Lymphoma
Show Display Options
Rank Status Study
1 Active, not recruiting Tandem Auto-Allo Transplant for Lymphoma
Conditions: Diffuse, Large B-Cell, Lymphoma;   Lymphoma, Low-Grade;   T-Cell Lymphoma;   Mantle-Cell Lymphoma;   Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
Interventions: Drug: Busulfan;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Phenytoin;   Drug: Ursodiol;   Other: Infusion of autologous peripheral blood stem cells;   Drug: Neupogen;   Drug: Fludarabine;   Other: Peripheral blood stem cell transplant;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Methotrexate
2 Completed Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat
Conditions: Hodgkin's Lymphoma;   Low Grade Lymphoma;   Lymphoma;   Mantle Cell Lymphoma;   Non-Hodgkin's Lymphoma;   Diffuse Large Cell Lymphoma
Interventions: Drug: AMG 655;   Other: Vorinostat;   Other: Bortezomib
3 Active, not recruiting First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma
Interventions: Drug: Rituximab, Cyclophosphamide, Vincristine, Prednisone;   Drug: Rituximab, Cyclophosphamid, Doxorubicin, Vincristine, Prednisone
4 Recruiting Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Conditions: Indolent Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma
Intervention: Drug: Idelalisib
5 Unknown  Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-Grade Lymphoma in Adults
Conditions: Burkitt's Lymphoma;   Burkitt's Leukemia;   Mediastinal Neoplasms;   Lymphoblastic Lymphoma;   Large Cell Anaplastic Lymphoma
Interventions: Drug: Adriamycin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone/Prednisolone;   Drug: VP16;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: G-CSF;   Drug: Rituximab;   Drug: Vincristine/Vindesine;   Procedure: Irradiation (in specific conditions)
6 Withdrawn Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
Conditions: AIDS-related Lymphoma;   Adult Non-Hodgkin's Lymphoma;   Anaplastic Large Cell Lymphoma
Interventions: Drug: cisplatin;   Drug: cytarabine;   Drug: etoposide;   Drug: methylprednisolone;   Drug: rituximab;   Drug: yttrium Y 90 ibritumomab tiuxetan;   Procedure: antibody therapy;   Procedure: biological  therapy;   Procedure: chemotherapy;   Procedure: monoclonal antibody therapy;   Procedure: radiation therapy;   Procedure: radioimmunotherapy;   Procedure: radioisotope therapy
7 Terminated A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Eltrombopag and Vorinostat
8 Terminated
Has Results
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Conditions: Burkitt Lymphoma;   Non-Hodgkins Lymphoma;   Atypical Burkitt Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Leucovorin;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Mesna
9 Not yet recruiting CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: 6,8-bis(benzylthio)octanoic acid;   Drug: bendamustine hydrochloride;   Biological: rituximab;   Other: laboratory biomarker analysis
10 Completed Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Conditions: Childhood Burkitt Lymphoma;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Colon Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Melanoma;   Recurrent Nasopharyngeal Cancer;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: irinotecan hydrochloride;   Drug: oxaliplatin
11 Completed Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas
Conditions: Burkitt Lymphoma;   Lymphoma, Large-Cell, Diffuse;   Lymphoma, Small Noncleaved-Cell
Intervention: Drug: granulocyte-macrophage colony stimulating factor (GM-CSF)
12 Completed
Has Results
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma
Intervention: Drug: ixabepilone
13 Terminated Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: MTD of Velcade, Nipent and Rituxan established in Part 1
14 Completed Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
Conditions: Childhood Acute Promyelocytic Leukemia (M3);   Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Relapsing Chronic Myelogenous Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: vorinostat;   Drug: isotretinoin
15 Terminated
Has Results
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: ipilimumab;   Other: laboratory biomarker analysis
16 Terminated Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas
Conditions: Non-Hodgkin's Lymphoma;   Burkitt Lymphoma;   Primary Effusion Lymphomas
Intervention: Drug: Pegylated Liposomal Doxorubicin (Doxil) and Rituximab
17 Unknown  Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation
Conditions: Lymphoma;   Lymphoma, Non-Hodgkin
Interventions: Drug: proton pump inhibitor;   Drug: clarithromycin;   Drug: amoxicillin;   Drug: metronidazole;   Procedure: radiation therapy
18 Recruiting Ipilimumab and Rituximab In Treating Patients With Relapsed or Refractory B-Cell Lymphoma
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: ipilimumab;   Biological: rituximab;   Other: laboratory biomarker analysis
19 Completed
Has Results
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
Conditions: Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: oblimersen sodium;   Biological: rituximab;   Other: laboratory biomarker analysis
20 Completed Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Biological: DI-Leu16-IL2 immunocytokine;   Biological: rituximab;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Genetic: reverse transcriptase-polymerase chain reaction

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years